An inhibin A test measures a reproductive hormone made mainly by ovarian granulosa cells and, during pregnancy, by the placenta. The result has very different meanings depending on why the test was ordered. In the second trimester, inhibin A is one of four markers in the maternal serum quad screen used to estimate the chance of certain fetal chromosome conditions, especially trisomy 21. It is a screening marker, not a diagnosis. Outside pregnancy, inhibin A may help evaluate or monitor selected ovarian tumors, particularly granulosa cell tumors, but it is not a routine ovarian reserve or fertility test. Levels change with menstrual phase, age, menopause, pregnancy, laboratory method, and clinical context, so there is no single “healthy” value that applies to every woman. Results should be interpreted with the full screening calculation, imaging, symptoms, and other laboratory findings rather than on their own.
- Inhibin A is produced by ovarian granulosa cells and rises greatly during pregnancy because the placenta also releases it.
- In the quad screen, high inhibin A together with high hCG and low AFP and estriol can increase the estimated chance of trisomy 21.
- A positive prenatal screen does not diagnose Down syndrome; ultrasound, cell-free DNA screening, or diagnostic testing may be offered next.
- Inhibin A is not a standard test of egg count or fertility and cannot reliably predict natural conception by itself.
- After menopause, inhibin A is normally very low, so an unexplained elevation may prompt evaluation for an inhibin-producing ovarian tumor.
- Reference ranges vary widely by pregnancy week, menstrual phase, menopausal status, and laboratory method.
Table of Contents
- What Inhibin A Is
- Why the Test Is Ordered
- Inhibin A in Pregnancy Screening
- Inhibin A and Ovarian Function
- High and Low Results
- Preparation and Test Timing
- Follow-Up After an Abnormal Result
- Limits and Common Misunderstandings
What Inhibin A Is
Inhibin A is a glycoprotein hormone made from an alpha subunit joined to a beta-A subunit. In nonpregnant women, it is secreted mainly by granulosa cells, the cells that surround and support developing eggs inside ovarian follicles. Its best-known physiological action is to reduce secretion of follicle-stimulating hormone, or FSH, from the pituitary gland.
The ovaries do not release inhibin A at a constant rate. Levels are generally lower during the early follicular phase and rise after ovulation as the corpus luteum develops. This cycle-related variation is one reason an isolated result is difficult to use as a broad measure of ovarian health. The closely related hormone inhibin B is more prominent earlier in the menstrual cycle and is more often studied in relation to follicle activity. A separate inhibin B test in women therefore answers somewhat different questions.
During pregnancy, the placenta becomes a major source of inhibin A. Concentrations change with gestational age and are interpreted as a multiple of the median, usually written MoM, rather than as a raw concentration alone. A value of 1.0 MoM is near the median expected for a pregnancy at that gestational age after adjustments are applied. The screening program may adjust for maternal weight, age, diabetes, race or ethnicity where locally used, smoking, number of fetuses, and assisted conception.
Inhibin A is also produced by some ovarian tumors. Adult-type granulosa cell tumors are uncommon sex cord-stromal tumors that may release inhibin A, inhibin B, estradiol, or other hormones. Because healthy postmenopausal ovaries usually produce little inhibin, an elevated result can be more conspicuous after menopause. Even then, inhibin A is a tumor marker rather than a stand-alone cancer test.
The test is performed on a venous blood sample. Laboratories may use immunoassays designed for prenatal screening or tumor-marker assessment. Those assays are not always interchangeable, and the report should state the intended use and reference framework.
Why the Test Is Ordered
The reason for testing determines how the result should be read. Inhibin A is most commonly encountered in one of three settings: prenatal screening, evaluation of a suspected ovarian sex cord-stromal tumor, or follow-up of a previously diagnosed inhibin-producing tumor.
Second-trimester prenatal screening
Inhibin A is one component of the quad screen. The other three markers are alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. The panel combines these biochemical results with pregnancy and maternal information to calculate a chance estimate for fetal trisomy 21 and, depending on the program, trisomy 18 and open neural tube defects.
The quad screen is often offered when first-trimester screening or cell-free DNA screening was not performed, is unavailable, or is not the chosen option. It may also be part of an integrated screening pathway. The timing and local use vary, but testing is commonly performed between 15 and 22 weeks, with many laboratories preferring approximately 16 to 18 weeks for the most reliable performance.
Ovarian tumor assessment
A clinician may order inhibin A when a pelvic mass, abnormal uterine bleeding, estrogen-related symptoms, or imaging raises concern for a granulosa cell tumor. These tumors can occur at different ages and may produce estrogen, causing irregular bleeding, endometrial thickening, or early puberty in children. Inhibin A is usually combined with imaging, clinical findings, inhibin B, and sometimes other markers such as anti-Müllerian hormone or CA-125.
Testing may also establish a personal tumor-marker baseline before treatment. If inhibin A is high when the tumor is present and falls after surgery, later increases may help detect recurrence. Long-term surveillance can matter because granulosa cell tumors may recur years after initial treatment.
Ovarian function questions
Inhibin A reflects ovarian activity, but clinicians rarely order it as a routine fertility or menopause test. More established tools include cycle-timed FSH and estradiol, anti-Müllerian hormone, and antral follicle count. An ovarian reserve test panel may include inhibin B in selected settings, but inhibin A is not a standard marker of the remaining egg supply.
If inhibin A appears on a broad direct-to-consumer hormone panel, its meaning should be questioned before conclusions are drawn. A number can be biologically real yet clinically unhelpful when the test was not ordered for a validated indication.
Inhibin A in Pregnancy Screening
In prenatal screening, inhibin A is interpreted as part of a pattern. It is not judged with a general nonpregnant reference range and should not be viewed separately from gestational age and the other markers.
The classic second-trimester pattern associated with trisomy 21 is:
- lower alpha-fetoprotein;
- higher hCG;
- lower unconjugated estriol;
- higher inhibin A.
The exact screening calculation is performed by validated software. In pregnancies affected by trisomy 21, inhibin A is often around twice the median, but there is substantial overlap with unaffected pregnancies. That overlap explains why the marker cannot diagnose a chromosome condition.
A high inhibin A result can increase the calculated chance of trisomy 21, especially when the other markers follow the same pattern. The final report may use terms such as screen positive, increased chance, high risk, or above cutoff. It may show a ratio such as 1 in 100 or 1 in 250. A ratio of 1 in 100 means that among pregnancies with the same screening profile, about one would be expected to have the condition and 99 would not. It does not mean the fetus is “100 times abnormal,” and it is not a percentage unless converted correctly.
A screen-negative result lowers the estimated chance but does not make it zero. No prenatal screening test identifies every affected pregnancy. The performance of quad screening is also lower than modern cell-free DNA screening for common trisomies, although the quad screen provides information about AFP and open neural tube defect risk that cell-free DNA does not replace.
The related estriol test in pregnancy contributes separate placental and fetal information. Interpreting one marker in isolation can distort the meaning of the panel.
Why dates and pregnancy details matter
Incorrect gestational age is a common reason for an unexpected screen. Marker medians change from week to week, so dating errors can make an otherwise normal value appear abnormal. An ultrasound may be used to confirm fetal age, number of fetuses, viability, and anatomy.
Maternal weight affects blood marker concentrations because of dilution in a larger plasma volume. Multiple pregnancy, insulin-treated diabetes, smoking, donor eggs, and assisted reproductive technology may also affect calculations. The laboratory needs accurate information to produce a valid estimate.
Elevated inhibin A and pregnancy complications
An unexplained high inhibin A level has been associated in observational studies with placental complications such as preeclampsia, fetal growth restriction, and preterm birth. Association does not mean that the marker can accurately predict which individual pregnancy will develop a complication. Inhibin A alone is not a standard diagnostic test for preeclampsia.
A clinician may consider the entire screening profile, blood pressure, obstetric history, ultrasound findings, and other risk factors when planning follow-up. Some practices use abnormal serum analytes as one reason to pay closer attention to fetal growth or placental function later in pregnancy, but management varies by guideline and individual risk.
Inhibin A and Ovarian Function
Inhibin A participates in the feedback loop between the ovary and pituitary gland. After ovulation, the corpus luteum releases inhibin A along with progesterone and estradiol. Inhibin A helps suppress FSH during the luteal phase, contributing to the timing of the next follicular wave.
This biology does not make inhibin A a precise fertility score. Ovarian reserve refers mainly to the quantity of remaining follicles, not the quality of every egg or the likelihood of pregnancy in a particular month. Inhibin A varies with cycle phase and luteal function and has not become a routine reserve marker.
AMH and antral follicle count are generally more stable or useful for estimating response to ovarian stimulation. Early-follicular FSH and estradiol may add context, especially when interpreted together. The AMH test in women still has important limitations: it cannot directly measure egg quality, guarantee pregnancy, or give an exact menopause date.
Inhibin A usually declines as follicle activity falls with age and becomes very low after menopause. A low result in a postmenopausal woman is expected and does not require treatment. In a menstruating woman, a low level may simply reflect the phase of the cycle. Without a defined clinical question and cycle timing, the number offers little information.
A high inhibin A level can suppress FSH, but common reproductive disorders are not diagnosed from this relationship alone. Polycystic ovary syndrome, luteal dysfunction, hypothalamic amenorrhea, and premature ovarian insufficiency require broader clinical and hormonal assessment. A female hormone test panel may be appropriate when periods or fertility are being evaluated, but testing should be selected rather than ordered indiscriminately.
Inhibin A as a tumor marker
Granulosa cell tumors can produce inhibin A and inhibin B. Published laboratory information suggests that inhibin A is elevated in a substantial proportion, but not all, of these tumors. Inhibin B may be more sensitive in some cases. A normal result therefore cannot rule out a tumor.
The marker is most useful when it is elevated before treatment. A falling value can support treatment response, while a rising trend may prompt imaging or specialist assessment. Trend interpretation should use the same laboratory when possible because assay methods differ.
Other benign and malignant ovarian conditions can also affect inhibin results. A high marker does not prove cancer, and no blood test can reliably determine whether an ovarian mass is benign or malignant without imaging and, when necessary, tissue diagnosis.
High and Low Results
The same result can have different meanings in pregnancy, before menopause, and after menopause. The report’s reference interval and indication are essential.
| Clinical setting | Higher result may suggest | Lower result may suggest |
|---|---|---|
| Second-trimester quad screen | Part of a trisomy 21 screening pattern; possible placental association | Usually interpreted only within the full panel and risk calculation |
| Premenopausal, not pregnant | Cycle-phase effect, ovarian hormone production, or an inhibin-producing mass | Early-cycle timing, reduced follicle or luteal activity, or normal variation |
| Postmenopausal | Needs evaluation when clearly above the laboratory limit, especially with a pelvic mass | Expected finding |
| After treatment for granulosa cell tumor | Possible persistent or recurrent disease if the marker was previously informative | May support treatment response, but does not replace surveillance |
Laboratories that use inhibin A as a tumor marker may report a premenopausal upper limit around 90 to 100 pg/mL and a postmenopausal upper limit near 5 pg/mL, but these figures are assay-specific. Premenopausal levels change throughout the cycle, so a single upper cutoff is not a fertility target. Prenatal laboratories use gestational medians and MoM values instead of these tumor-marker limits.
Causes of a high inhibin A result
Possible explanations include:
- normal pregnancy-related placental production;
- a quad-screen pattern associated with increased trisomy 21 chance;
- inaccurate gestational dating or incorrect screening information;
- multiple pregnancy;
- placental dysfunction or an association with later pregnancy complications;
- an ovarian granulosa cell tumor or another inhibin-producing ovarian tumor;
- normal menstrual-cycle variation;
- laboratory or specimen error.
The result should never be interpreted from the word “high” alone. A 2.0 MoM pregnancy result is not equivalent to a tumor-marker value twice the postmenopausal cutoff.
Causes of a low inhibin A result
Low inhibin A is often normal in the early follicular phase or after menopause. In a quad screen, low inhibin A has less specific meaning than the full combination of AFP, hCG, and estriol. It is not usually treated and does not prove ovarian failure.
When ovarian insufficiency is suspected, diagnosis relies on symptoms, menstrual history, and repeated FSH testing rather than inhibin A alone. The FSH test in women is more central in that evaluation.
Preparation and Test Timing
No fasting is usually required for an inhibin A blood test. A health professional draws blood from a vein, and the most common effects are brief discomfort or bruising.
Preparation is mainly about accurate clinical information. For prenatal screening, provide the best available gestational dating, maternal date of birth, weight, diabetes status, smoking status if requested, number of fetuses, and whether donor eggs or fertility treatment were used. Tell the laboratory if an ultrasound has revised the due date.
For nonpregnant testing, record the first day of the last menstrual period and the cycle day of collection. Mention hormonal contraception, fertility medicines, hormone replacement therapy, pregnancy possibility, and recent ovarian surgery. These factors may change interpretation.
Tumor-marker testing does not generally require a particular cycle day, but consistent timing can improve trend comparison in premenopausal women. When the marker is used for surveillance, using the same laboratory and assay is helpful.
Biotin can interfere with some immunoassays. Tell the clinician and laboratory about high-dose biotin supplements, but do not stop prescribed products without instructions. The laboratory can advise whether a pause is needed.
Follow-Up After an Abnormal Result
Follow-up should match the reason for testing. An abnormal prenatal screen and an elevated tumor marker require very different pathways.
After a screen-positive quad test
The first step is usually a careful review of dates and pregnancy information. Ultrasound may confirm gestational age and evaluate fetal anatomy. Genetic counseling can explain the estimated chance, test performance, and available choices without assuming that one option is right for everyone.
Further options may include:
- Cell-free DNA screening, which is more accurate for common trisomies but remains a screening test.
- Detailed ultrasound, including assessment for structural findings.
- Amniocentesis, usually performed after 15 weeks, for diagnostic chromosome testing.
- Declining further testing after informed discussion.
The choice depends on gestational age, the reported chance, ultrasound findings, personal values, and how much certainty is desired. Diagnostic testing examines fetal cells and can confirm or exclude the chromosome condition being tested, whereas a second screening test changes probability rather than providing certainty.
After an elevated nonpregnant result
A clinician may repeat inhibin A, order inhibin B or AMH, perform pelvic ultrasound, and review symptoms such as abnormal bleeding, pelvic pressure, abdominal swelling, early fullness, or pain. Referral to gynecology or gynecologic oncology may be appropriate when imaging identifies an adnexal mass or the result is markedly abnormal after menopause.
A modest isolated elevation in a menstruating woman may be repeated at a standardized cycle time before extensive investigation, depending on symptoms and imaging. In contrast, a persistent postmenopausal elevation with a pelvic mass warrants prompt specialist assessment.
For someone with a known granulosa cell tumor, surveillance may include periodic marker measurements and imaging over a long period. The schedule is individualized by the oncology team.
Limits and Common Misunderstandings
Inhibin A is a useful marker in narrow settings, but several common interpretations are inaccurate.
“High inhibin A means the baby has Down syndrome.” It does not. The quad screen estimates chance from four markers and personal data. Most screen-positive results are not diagnostic.
“Normal inhibin A rules out a chromosome condition.” It does not. Screening has false-negative results, and no single serum marker excludes trisomy 21.
“Inhibin A shows how many eggs are left.” It does not provide an egg count. Ovarian reserve assessment uses other measures, and even those cannot directly measure egg quality or natural fertility.
“A normal result rules out an ovarian tumor.” It does not. Some granulosa cell tumors do not raise inhibin A, and other evaluation remains necessary.
“One reference range works in every setting.” Prenatal screening uses gestational MoM values; tumor-marker testing uses sex- and menopause-specific intervals; menstrual-cycle physiology creates additional variation.
“An elevated marker should be treated directly.” Inhibin A itself is not treated. Clinicians identify the cause and manage the underlying pregnancy risk, tumor, or other condition.
Urgent care is not usually required for an isolated laboratory result, but symptoms can change the urgency. During pregnancy, seek prompt assessment for severe headache, vision changes, upper abdominal pain, sudden swelling, bleeding, fluid leakage, reduced fetal movement later in pregnancy, or signs of preterm labor. Outside pregnancy, rapidly increasing abdominal swelling, severe pelvic pain, fainting, or heavy bleeding also needs timely evaluation.
The most useful interpretation begins with one question: was the test ordered for prenatal screening, ovarian tumor assessment, or another reason? Once that context is clear, inhibin A can add meaningful information without being mistaken for a diagnosis on its own.
References
- Prenatal Genetic Screening 2025 (Review)
- Biochemical Screening for Fetal Trisomy 21 2023 (Review)
- Quadruple screen test 2026 (Official Page)
- Adult-type granulosa cell tumor of the ovary 2022 (Review)
- Association of serum inhibin A with pre-eclampsia: An observational cohort study 2024 (Cohort Study)
- INHAB – Overview: Inhibin A and B, Tumor Marker, Serum 2026 (Official Laboratory Reference)
Disclaimer
This article provides general information and cannot interpret an individual inhibin A result or prenatal risk calculation. Pregnancy screening decisions and evaluation of possible ovarian tumors should be discussed with an obstetric clinician, genetic counselor, gynecologist, or oncologist as appropriate. Seek urgent care for severe pregnancy warning symptoms, heavy bleeding, sudden pelvic pain, or other acute concerns.
